# Propranolol

Drug · id `cardio:propranolol` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Browse, organ or system: Heart  
Browse, condition area: High blood pressure; Coronary and vascular disease; Heart rhythm problems  

## In plain language

Propranolol is a beta-blocker. The US label read, for propranolol hydrochloride tablets (taken by mouth), lists several heart and vessel uses, of which this page records four: hypertension; decreasing angina frequency and increasing exercise tolerance in patients with angina pectoris; controlling the ventricular rate in atrial fibrillation with a rapid ventricular response; and reducing cardiovascular mortality in stable patients who have survived the acute phase of a myocardial infarction. The label also lists another heart use and uses outside the heart, which this page does not record.

## Technical summary

RxNorm ingredient 8787; UNII F8A3652H1V. The label names the substance as propranolol hydrochloride, so UNII F8A3652H1V is the UNII of the hydrochloride salt and is a broad match. MeSH descriptor D011433 is Propranolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Amneal Pharmaceuticals NY LLC label for propranolol hydrochloride tablets, applications ANDA071972 and ANDA071976, effective 2026-06-10 in openFDA. The tablet label of a generic sponsor was read because it is a plain immediate-release tablet label; the Inderal LA, InnoPran XL and Hemangeol labels (other products of the same substance) were not read. This page records label indications and the class only: no trial result and no dose is given. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded.

## Claims, with the population each applies to

## Context: People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction

Recipient: Recipient not specified; Population: Patients described in the heart and vessel passages of the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Propranolol hydrochloride tablets, in the Amneal Pharmaceuticals NY LLC version dated 2026-06-10 in openFDA, lists the medicine for the management of hypertension; to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response; and to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of myocardial infarction.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the heart and vessel passages of the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-08
- Sources:
  1. Supports: openFDA drug label record for Propranolol hydrochloride tablets, Amneal Pharmaceuticals NY LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 14d0c95d-418f-40a8-bad3-e20c82424960 (manufacturer Amneal Pharmaceuticals NY LLC, application ANDA071972 and ANDA071976), returned on 2026-11-08. The label text is dated 2026-06-10 (effective\_time). Other openFDA records of propranolol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2214d0c95d-418f-40a8-bad3-e20c82424960%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-08T20:38:25Z. Source state: Current. Version fingerprint: 58aa79ab4fa6d5f88acbbfcb992c5236ebf3aee11476e255e1eefae3929e0d7d.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for Propranolol hydrochloride tablets, Amneal Pharmaceuticals NY LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 14d0c95d-418f-40a8-bad3-e20c82424960 (manufacturer Amneal Pharmaceuticals NY LLC, application ANDA071972 and ANDA071976), returned on 2026-11-08. The label text is dated 2026-06-10 (effective\_time). Other openFDA records of propranolol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2214d0c95d-418f-40a8-bad3-e20c82424960%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T20:38:25Z. Source state: Current. Version fingerprint: 58aa79ab4fa6d5f88acbbfcb992c5236ebf3aee11476e255e1eefae3929e0d7d.
     How it applies: Effective date of the label text read, 20260610.

## Connected pages

- Propranolol is a beta-adrenergic blocker (FDA established pharmacologic class in RxClass): Beta-blockers (drug class) (`cardio:beta-blockers`)
- FDA label lists management of hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-propranolol-label-indications` and its context]
- FDA label lists control of ventricular rate in atrial fibrillation with a rapid ventricular response as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-propranolol-label-indications` and its context]
- FDA label lists reducing cardiovascular mortality after the acute phase of myocardial infarction as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-propranolol-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 8 registry products
- 1 registry trial

## Provenance

Content hash: 977dc904e56a1c9095fd9e83a708cab1f569c8640f4f6d61167bc7bec2eb9d15
Last substantive edit: 2026-11-08
Evidence last checked: 2026-11-08
